Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.3 USD | -9.61% |
|
-9.74% | -45.50% |
06-27 | European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading | MT |
06-27 | Grifols Shares Fall Premarket Following Downgrade by Moody's | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- With a P/E ratio at 11.85 for the current year and 7.48 for next year, earnings multiples are highly attractive compared with competitors.
- The company appears to be poorly valued given its net asset value.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- One of the major weak points of the company is its financial situation.
- The company is not the most generous with respect to shareholders' compensation.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-45.50% | 5.15B | - | ||
+2.99% | 94.76B | A- | ||
-3.68% | 37.58B | A- | ||
-11.61% | 33.3B | B- | ||
+75.79% | 27.92B | A | ||
-13.40% | 15.85B | C | ||
-2.29% | 13.79B | B- | ||
-12.21% | 11.51B | D+ | ||
+188.83% | 10.9B | D | ||
-53.94% | 9.27B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- GRF Stock
- GRFS Stock
- Ratings Grifols, S.A.